Anne Murati

ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia

Véronique Gelsi‐Boyer, Virginie Trouplin, Julien Roquain et al. · British Journal of Haematology · 2010 · 217 citations · Full text

Medicine, Hematology, Molecular Genetics +17

Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias

Julien Rocquain, Nadine Carbuccia, Virginie Trouplin et al. · BMC Cancer · 2010 · 171 citations · Full text

Medicine, Genetics, Hematology +17

Mutation analysis of <i>ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12,</i> and <i>TET2</i> in myeloproliferative neoplasms

Mandy Brecqueville, Jérôme Rey, François Bertucci et al. · Genes Chromosomes and Cancer · 2012 · 153 citations

Medicine, Genetics, Molecular Genetics +17

Role of<i>ASXL1</i>and<i>TP53</i>mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes

Raynier Devillier, Véronique Mansat‐De Mas, Véronique Gelsi‐Boyer et al. · Oncotarget · 2015 · 79 citations · Full text

Life Sciences, Molecular Biology, Molecular Genetics +17

Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of <i>ASXL1</i> mutations: a FIM study

Damien Luque Paz, Jérémie Riou, Emmanuelle Verger et al. · Blood Advances · 2021 · 75 citations · Full text

Medicine, Genetics, Molecular Genetics +17